Amarin Corp Plc (AMRN)

[dogn]

Info on BRAVE trial from piggybacking TBI study

Came across poster P03- VETERANS IN AD PREVENTION CLINICAL TRIALS: AN EVALUATION OF THE ASSOCIATION OF TBI ON MEMORY AND GLOBAL COGNITION from 14th Conference Clinical Trials on Alzheimer's Disease, Therapeutic Trials in AD: A New Hope for 2022?
Held Nov. 9-12, 2021 Boston

TBI=Traumatic Brain Injury
https://www.ctad-alzheimer.com/files/files/CTAD21%20Posters.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589634/

Methods: Participants were drawn from an on-going 18-month, randomized, placebo-controlled clinical trial studying the effects of high-dose eicosapentaenoic acid (icosapent ethyl) on neuroimaging and cerebrospinal fluid AD biomarkers and cognition; the Brain Amyloid and Vascular Effects (BRAVE) of Eicosapentaenoic Acid Study (NCT02719327). Participants were VA -eligible Veterans ages 50–75 with no diagnosis of memory disorder or impairment. Participants were excluded if they were unable to safely take the study medication or participate in MRI or lumbar puncture procedures. Study analyses included N=114 Veterans who were seen for a prestudy screening and baseline visit. Cognitive assessments were administered prior to randomization.
...
Results: Most enrollees in BRAVE are male (N=94, 86%) and white (107, 97%). Mean age is 65.5 years (SD = 6.7). Seventeen enrollees (15%) report no college experience, 29 have an associate’s degree or degree from a technical school (26%), 25 report some college experience but no degree (23%), 25 (23%) have a 4 year degree, and 14 reported some post-baccalaureate college (13%). Half (N=55) of enrollees met criteria for TBI; 27 indicated the event occurred during deployment. TBI and non-TBI groups were comparable on age, education, gender, race, and depression rating. ...
In this study, the probable TBI group was indistinguishable from the non-TBI group on baseline measures of memory and outperformed the non-TBI group on measure of global cognition. ... TBI has been shown to lower the age of dementia onset, however, the BRAVE sample is relatively young and may not be experiencing even subtle cognitive deficits yet.

Thought it interesting as don't recall seeing such info on BRAVE enrollee demographics.
dogn